Compare PayPal Holdings, Inc. (PYPL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PayPal Holdings, Inc. vs Tango Therapeutics Inc. — how do they compare? PayPal Holdings, Inc. trades at $56.17 (market cap $48.05B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: PayPal Holdings, Inc. is far larger — about 12.8× Tango Therapeutics Inc.'s market cap, and PayPal Holdings, Inc. pays a 1% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold PayPal Holdings, Inc. for 106 Days and Tango Therapeutics Inc. for 0 Days on average.
| PYPL | TNGX | |
|---|---|---|
Market Cap | $48.05B | $3.75B |
Volume | 7,905,570 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $73.01 | $32.90 |
52-Week Low | $39.08 | $7.50 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $50.20B | $2.77B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PayPal trades at $56.10, up 0.09% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $31.8B in 2024 to $33.2B in 2025 and net income of $5.23B. Valuation metrics appear attractive with P/E of 10.62 and EV/EBITDA of 6.89. Recent Q2 2026 earnings beat expectations at $1.38 EPS versus $1.28 expected. The company maintains robust cash flow with $1.53B net cash flow in 2025 and recently announced a Meta partnership for AI-powered checkout.
PayPal presents a compelling value opportunity with reasonable valuation and solid financials, though faces competitive pressures in digital payments. Analyst consensus is mixed with 35.7% buy ratings but a $56.41 price target suggesting limited upside. Key risks include checkout competition and slowing growth, balanced by new CEO's turnaround focus on Venmo, BNPL, and cost efficiency initiatives.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
